Pancreatic Cancer Research

ResearcherUniversity of TorontoNo recent work listed

Ambica Parmar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0597-3843; OpenAlex author ID A5017907374. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

  1. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac047↗
  2. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. Co-author DOI 10.1016/j.critrevonc.2019.102817↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kelvin Chan · 2 shared papers, 2020–2022 · strength 0.24
  2. Vanessa Sarah Arciero · 1 shared paper, 2022 · strength 0.13
  3. Wei Fang Dai · 1 shared paper, 2022 · strength 0.13
  4. Michael Jonathon Raphael · 1 shared paper, 2022 · strength 0.13
  5. Nicole Mittmann · 1 shared paper, 2022 · strength 0.13
  6. Yoo‐Joung Ko · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.